Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECLAIM-LN: FT819 in Refractory Moderate-to-Severe Systemic Lupus Erythematosus With Lupus Nephritis
NCT07570862Phase 2Recruiting
- Sponsor
- Fate Therapeutics
- Start
- Jul 2026
- Primary completion
- Jul 2029
- Modality
- CAR-T Cells, Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
A Phase 2 trial of FT819 in systemic lupus erythematosus (SLE), lupus nephritis (LN), sponsored by Fate Therapeutics. Started Jul 2026; status: recruiting.
02
Drugs
FT819
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT07570862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07570862.